Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 27:11:1472064.
doi: 10.3389/fcvm.2024.1472064. eCollection 2024.

The efficacy and safety of atherectomy combined with drug-coated balloon angioplasty vs. drug-coated balloon angioplasty for the treatment of lower extremity artery disease: a systematic review and meta-analysis

Margareta Ginanti Ratna Indraswari Suriyanto  1 , Raymond Pranata  1 , William Kamarullah  1 , Iwan Cahyo Santosa Putra  1 , Dendi Puji Wahyudi  1 , Giky Karwiky  1 , Teddy Arnold Sihite  1 , Mohammad Rizki Akbar  1 , Januar Wibawa Martha  1 , Syarief Hidayat  1
Affiliations

The efficacy and safety of atherectomy combined with drug-coated balloon angioplasty vs. drug-coated balloon angioplasty for the treatment of lower extremity artery disease: a systematic review and meta-analysis

Margareta Ginanti Ratna Indraswari Suriyanto et al. Front Cardiovasc Med. .

Abstract

Background: This study aimed to systematically evaluate the efficacy and safety of atherectomy followed by drug-coated balloon angioplasty (A-DCB) in comparison with drug-coated balloon (DCB) angioplasty alone for the treatment of lower extremity artery disease (LEAD).

Methods: Systematic literature search was performed using several online databases including MEDLINE (via PubMed), Europe PMC, and ScienceDirect databases from inception until February 21st, 2024. We included all studies comprised three main variables including A-DCB, DCB, and LEAD. The primary outcomes were primary patency and target lesion revascularization (TLR). Whereas secondary outcomes were all-cause mortality, post-procedural complications, and clinical characteristics.

Results: A total of 15 studies (10 cohort studies and 5 randomized controlled trials studies) consisting of 1,385 participants with mean age 68.7 ± 8.9 were included. In comparison with DCB alone, A-DCB was significantly associated with a higher risk of primary patency [RR = 1.16 (95% CI = 1.07-1.26); P < 0.001; I 2 = 20.9%, P-heterogeneity = 0.221] and lower risk of TLR [RR = 0.61 (95% CI = 0.46-0.81); P < 0.001; I 2 = 0%, P-heterogeneity = 0.475]. Subgroup analysis showed that only directional, rotational, and laser atherectomy increased the probability of primary patency, but only rotational atherectomy decreased the risk of TLR. Regarding secondary outcomes, A-DCB was substantially associated with a lower likelihood of bailout stenting, any amputation, and major amputation, as well as higher ankle brachial index (ABI) following follow-up duration. Meta-regression analysis suggested that pre-intervention s (p = 0.015) and pre-intervention Rutherford classification (p = 0.038) were significantly affected the association between A-DCB and primary patency. Begg's funnel plot and Egger's test analyses indicated no publication bias in this meta-analysis.

Conclusions: The addition of atherectomy improves primary patency and reduces the risk of TLR with similar safety outcomes.

Systematic review registration: www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022382831, PROSPERO (CRD42022382831).

Keywords: angioplasty; atherectomy; directional atherectomy; drug-coated balloon angioplasty; lower extremity artery disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of study selection process.
Figure 2
Figure 2
Meta-analysis of atherectomy followed by DCB angioplasty and primary outcomes.
Figure 3
Figure 3
Funnel plot analysis for primary patency and TLR.
Figure 4
Figure 4
Central illustration.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lin J, Chen Y, Jiang N, Li Z, Xu S. Burden of peripheral artery disease and its attributable risk factors in 204 countries and territories from 1990 to 2019. Front Cardiovasc Med. (2022) 9:868370. 10.3389/fcvm.2022.868370 - DOI - PMC - PubMed
    1. Aboyans V, Sevestre MA, Désormais I, Lacroix P, Fowkes G, Criqui MH. Epidemiology of lower extremity artery disease. Presse Med. (2018) 47:38–46. 10.1016/j.lpm.2018.01.012 - DOI - PubMed
    1. Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries endorsed by: the European Stroke Organization (ESO)The task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. (2018) 39:763–816. 10.1093/eurheartj/ehx095 - DOI - PubMed
    1. Anantha-Narayanan M, Shah SM, Jelani QUA, Garcia S, Ionescu C, Regan C, et al. Drug-coated balloon versus plain old balloon angioplasty in femoropopliteal disease: an updated meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv. (2019) 94:139–48. 10.1002/ccd.28176 - DOI - PubMed
    1. Nugraha HG, Hilman S, Santiana L, Dewi DK, Raffaelo WM, Wibowo A, et al. Drug-coated balloon versus drug-eluting stent in patients with femoropopliteal artery disease: a systematic review and meta-analysis. Vasc Endovascular Surg. (2022) 56:385–92. 10.1177/15385744211051491 - DOI - PubMed

Publication types

LinkOut - more resources